Immunotherapy

This is a treatment that uses your own immune system to fight disease. It's like giving your body's natural defenses a boost or helping them work better. It can involve using vaccines or special medicines to stimulate your immune system.

Therapy

What people using Immunotherapy report

Every report comes from a Lived member, sent anonymously.

Have you tried Immunotherapy for Neuroblastoma?

NameHow it went

About Immunotherapy

How It Works

Immunotherapy is treatment that works through the immune system rather than attacking a disease directly. The term is used most often for cancer care, where the goal is to help the body's own immune cells recognize and destroy cancer cells. The immune system normally clears out many abnormal cells, but cancers survive partly by evading it. Some tumors are hard for immune cells to see, and some display proteins that switch immune cells off. The most widely used cancer immunotherapies, called immune checkpoint inhibitors, block those off switches. Checkpoints are built-in brakes that keep immune responses from damaging healthy tissue; releasing them lets T cells (the immune cells that kill infected or abnormal cells) attack the cancer more strongly. Other approaches collect a person's own T cells and strengthen or re-engineer them in a lab, use lab-made antibodies that tag cancer cells for destruction, or boost immune activity more generally. The same word is also used for allergy shots, which work in the opposite direction. Instead of stimulating the immune system, they expose it to gradually increasing doses of an allergen so that it becomes less reactive over time.

Who It's For

Cancer immunotherapy is approved for some people with many types of cancer, including melanoma and other skin cancers, lung, kidney, bladder, head and neck, liver, stomach, colon and rectal, cervical and breast cancers, and Hodgkin lymphoma. Some checkpoint inhibitors are also approved for solid tumors of any type that carry a specific defect in DNA repair, identified by testing the tumor. Engineered T-cell treatments called CAR T-cell therapy (CAR stands for chimeric antigen receptor, a lab-built receptor that steers T cells to the cancer) are used for certain blood cancers, such as some lymphomas, leukemias and multiple myeloma. Whether immunotherapy fits depends on the cancer's type and stage, results of tumor testing, earlier treatments and overall health. It may be given alone, combined with another immunotherapy, or added to chemotherapy, surgery or radiation. For some cancers it is now a standard first treatment; for others it is used after other treatments or only in clinical trials. Allergy shots are a separate option for people with hay fever or allergic asthma when testing confirms the triggers and medicines or avoidance are not controlling symptoms well enough. For insect sting allergy, they are used by people who have had a serious reaction to a sting and whose testing confirms the venom allergy. They can be given to children as young as about 5.

What It Involves

Checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) are antibody drugs usually given through a vein in an outpatient clinic, typically every few weeks; some are now also available as an injection under the skin. Other forms of immunotherapy are taken as pills, applied as a cream for very early skin cancers, or placed directly into the bladder. Before each dose the care team usually checks symptoms and blood tests, and treatment often continues for months as long as it is working and side effects stay manageable. CAR T-cell therapy is a more intensive, one-time process. A person's T cells are collected from the blood, modified in a lab over several weeks, and infused back after a short course of chemotherapy that makes room for them. Because serious reactions can develop in the days afterward, people are asked to stay close to the treatment center and not drive for at least 2 weeks after the infusion. Allergy shots begin with a build-up phase of injections once or twice a week for roughly 3 to 6 months, followed by maintenance shots every 2 to 4 weeks for 3 to 5 years. Each shot is given in a clinic, with a waiting period afterward so staff can watch for a reaction. Under-the-tongue allergy tablets are an alternative approved by the US Food and Drug Administration (FDA) for grass pollen, ragweed and dust mite allergy.

What to Expect

Progress with cancer immunotherapy is measured with physical exams, blood tests and scans that track the size of tumors. Responses vary widely. Some people see tumors shrink and stay controlled for years, some see the cancer stop growing, and many do not benefit. When it does work, the benefit can last for years in some people. Many people continue daily activities during checkpoint inhibitor treatment. Common side effects are tiredness, rash or itching, and diarrhea. Because side effects can begin months into treatment or even after it has ended, people are asked to tell any other clinician they see that they have received immunotherapy. With allergy shots, improvement usually builds gradually during the first year of maintenance. If symptoms have not improved after about a year of maintenance, the allergist will usually reconsider the plan.

What the Evidence Says

Immune checkpoint inhibitors have changed the outlook for several cancers, most clearly advanced melanoma. In a large randomized trial of people with previously untreated advanced melanoma, those given nivolumab plus ipilimumab (another checkpoint inhibitor) lived a median of about 6 years (meaning half the group was still alive at that point), compared with about 3 years on nivolumab alone and under 2 years on ipilimumab alone. Among people whose cancer had not progressed after 3 years, about 96 percent had not died of melanoma 10 years later. These results do not apply equally to every cancer or every person. The National Cancer Institute notes that only a minority of people who receive immunotherapy respond, and reliably predicting who will benefit remains an unsolved problem. Tumor tests, such as measuring PD-L1 (one of the off-switch proteins some tumors display) or looking for defects in DNA repair, help guide choices for some cancers, but they are imperfect. CAR T-cell therapy is approved for certain blood cancers, while its use in solid tumors such as breast and brain cancers is still experimental. For allergies, shots can substantially reduce symptoms and the need for medicine, may prevent new allergies, and can reduce the risk of severe reactions to insect stings. Relief is most likely to last after stopping when treatment continues for at least 3 years.

Risks & Considerations

Because cancer immunotherapy turns up the immune system, it can also attack healthy organs. With checkpoint inhibitors this can inflame the skin, bowel, lungs, liver, kidneys, nerves, heart or hormone glands such as the thyroid and pituitary. Signs depend on the organ: new diarrhea or belly pain, cough or shortness of breath, rash, yellowing skin, chest pain or a racing heartbeat, unusual fatigue, headache or dizziness. These problems can appear at any time, including months after the last dose, so new symptoms are worth reporting to the cancer care team promptly rather than waiting for the next visit. More significant ones are usually treated by pausing immunotherapy and giving corticosteroids, which calm the immune response. A few can be severe or fatal, and some hormone problems are permanent and require lifelong hormone replacement, such as thyroid medicine. Some situations change the balance of risk. People with an autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease can have flares, and people with an organ transplant can have rejection, so these need careful discussion before starting. Checkpoint inhibitors can harm a developing pregnancy. CAR T-cell therapy carries specific risks of cytokine release syndrome (a surge of immune signals causing fever, low blood pressure and trouble breathing) and of confusion or other nerve-related effects, which is why it is given only at specialized centers with close monitoring. In the weeks after the infusion, fever, chills, confusion, trouble speaking, shaking or trouble breathing need immediate contact with the treatment center, which gives a 24-hour number, rather than waiting for the next visit. Cost, travel and time away from work can also be substantial. Allergy shots commonly cause redness and swelling where the injection is given. Rarely, a shot triggers anaphylaxis, a severe whole-body allergic reaction with hives, throat tightness, trouble breathing or vomiting, which needs immediate emergency treatment. This is why shots are given in a clinic equipped to treat reactions and are not given at home.

Questions to Ask Your Doctor

  1. 1.Is immunotherapy a standard option for my type and stage of cancer, and do my tumor test results make a response more or less likely?
  2. 2.How will we know whether it is working, and what would make us stop or switch treatment?
  3. 3.Which symptoms should I report, how quickly, and who do I call after hours, including after treatment has ended?
  4. 4.Does my autoimmune condition, transplant, pregnancy plans or other medicines change whether this treatment is safe for me?
  5. 5.Are there clinical trials of immunotherapy that I should consider?

Last reviewed • Oct 2026

Educational content, not medical advice.